Delayed Australian S.E. 12:50:07 2024-04-02 am EDT 5-day change 1st Jan Change
0.0175 AUD -12.50% Intraday chart for HeraMED Limited 0.00% -27.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HeraMED Partners With FemBridge for Maternity Health Service; Shares Jump 15% MT
Heramed Limited Announces Board Changes CI
HeraMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HeraMED Enters Strategic Collaboration with PHI Research MT
HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director CI
HeraMED Enters Strategic Collaboration with GPEx MT
HeraMED Signs Deal with US-based Wingwomen for Cardio Initiative in Pregnant Women MT
HeraMED Concludes First Tranche of AU$1.25 Million Share Placement MT
HeraMED Signs Partnership Agreement with Telstra Health; Shares Climb 4% MT
HeraMED Launches Clinical Trial for Maternity Care Platform; Shares Surge 36% MT
HeraMED CEO Steps Down; CFO Transitions to EVP Role; Shares Surge 33% MT
HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect CI
HeraMED Limited Announces Resignation of David Groberman as Managing Director CI
HeraMED Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jianmin Pharmaceutical Group Co.,Ltd. completed the acquisition of 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd. CI
HeraMED Completes AU$2.58 Million Placement MT
HeraMED Transitions Chair to Executive Role MT
HeraMED's US Partner Signs Three-Year Commercial Deal with Caduceus Medical Group MT
HeraMED Signs Enterprise Agreement with Fond for HeraCARE Platform; Shares Decline 4% MT
Australian Shares Inch Down as Market Weighs Cooling, But Still High, US Inflation MT
Heramed Signs Deal with Perth-based Private OB-GYN Group for HeraCARE Deployment; Shares Climb 10% MT
Heramed Limited Announces Board Changes CI
Transcript : HeraMED Limited - Special Call
HeraMED Limited Auditor Raises 'Going Concern' Doubt CI
HeraMED Signs Deal with Queensland Public Healthcare Provider to Test Maternity Care Platform MT
Chart HeraMED Limited
More charts
Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for home and professional use. It offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The Company also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.
More about the company
  1. Stock Market
  2. Equities
  3. HMD Stock
  4. News HeraMED Limited
  5. HeraMED Achieves Positive Interim Results for Remote Maternity Care Device Pilot Program